Warning: session_start(): Cannot send session cookie - headers already sent by (output started at /home2/don/public_html/daily-enews-archives.php:5) in /home2/don/public_html/header08.php on line 1

Warning: session_start(): Cannot send session cache limiter - headers already sent (output started at /home2/don/public_html/daily-enews-archives.php:5) in /home2/don/public_html/header08.php on line 1
OBR Daily - Our Oncology Focused E-News Service

Register for OBR daily

Warning: Missing argument 1 for showSidebarBanner(), called in /home2/don/public_html/sidebar_obrgreen.php on line 38 and defined in /home2/don/public_html/include/banners.php on line 243

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

PARD $0.20 0.0500 +33.33%
CNDO $2.41 0.3600 +17.56%
ONTY $1.86 0.1700 +10.06%
NLNK $38.47 3.1900 +9.04%
IDRA $3.00 0.2000 +7.14%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

IMNP $2.62 -0.1300 -4.73%
Kite $42.96 -1.2400 -2.81%
ARGS $8.50 -0.2200 -2.52%
MEIP $6.73 -0.1600 -2.32%
SRNE $3.80 -0.0900 -2.31%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Next > | Last >>

Oncologists Can Control Healthcare Cost and Put Patients First

(Medscape Medical News) Nov 24, 2014 - Oncologists can play an important role in controlling healthcare costs and still maintain "the moral primacy of their duty to their individual patients," say the authors of a new commentary in the Journal of Clinical Oncology.
read article (free registration required) 

Zymeworks Inc. Announces Research Collaboration With Dr. Dennis J. Slamon and UCLA

(CNBC) Nov 25, 2014 - Zymeworks Inc. today announced it has entered into a collaboration with the University of California, Los Angeles through Dennis J. Slamon, M.D., Ph.D., to explore potential clinical indications in breast cancer for a number of Zymeworks’ bi-specific antibodies.
read article 

City of Hope Researchers Unlock the Potential of the Immune System to Fight Cancer

(City of Hope) Nov 24, 2014 - Among the diseases that City of Hope researchers are targeting with CAR T-cell therapy in current protocols are lymphoma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia.
read press release 

UC San Francisco and OncoSec Medical Collaborate to Evaluate Investigational Combination of ImmunoPulse and Anti-PD-1 Treatment

(MarketWatch) Nov 25, 2014 - OncoSec Medical Inc., a company developing DNA-based intratumoral cancer immunotherapies, has entered a clinical collaboration with the University of California, San Francisco (UCSF), to evaluate the safety, tolerability and efficacy of the combination of KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, and OncoSec’s ImmunoPulse (intratumoral IL-12) in metastatic melanoma.
read article 

Onxeo Announces Positive DSMB Recommendation For Its Phase III Trial With Livatag® in Primary Liver Cancer

(CNBC) Nov 24, 2014 - Onxeo SA, an innovative company specializing in the development of orphan oncology drugs, today announced that the European Independent Board of Experts (Data Safety and Monitoring Board, DSMB) in charge of the safety monitoring of the Livatag® Phase III trial has once again unanimously recommended continuing the study without modification.
read article 

Janssen Submits New Drug Application for YONDELIS® (trabectedin) to U.S. FDA For the Treatment of Patients With Advanced Soft Tissue Sarcoma

(Johnson & Johnson) Nov 24, 2014 - Janssen Research & Development, LLC has submitted a New Drug Application (NDA) for YONDELIS® (trabectedin) to the U.S. Food and Drug Administration (FDA) for the treatment of patients with advanced soft tissue sarcoma (STS), including liposarcoma and leiomyosarcoma subtypes, who have received prior chemotherapy including an anthracycline.
read corporate press release 

Radiologists Are Reducing the Pain of Uncertainty

(New York Times) Nov 24, 2014 - When Dr. Jennifer Kemp’s husband got advanced rectal cancer, she got an unexpected patient’s-eye view of her profession.
read article 

What's Hot at 2014 ASH

(Medscape Medical News) Nov 25, 2014 - The American Society of Hematology (ASH) 56th Annual Meeting will feature an array of phase 3 clinical trial results, a symposium on the cost of care, a lot of early data on promising experimental agents, and a second round of recommendations from the Choosing Wisely campaign, ASH officials told reporters.
read article (free registration required) 

Genclis SAS: Confirms Potential of Its Severidia(R) Test on 47 TNBC Patients

(Yahoo! Finance) Nov 25, 2014 - Genclis, a molecular diagnostic company in the fields of allergy and cancer, today presents additional clinical data for its molecular diagnostic test Severidia® in non-metastatic triple-negative breast cancer patients in the context of the 4th Munich Biomarker Conference, to be held in Munich, Germany, on November 25 and 26, 2014.
read article 

Synthon Initiates Treatment of First Patients in Phase I Trial of anti-HER2 ADC SYD985 Based on Its Proprietary Linker-Drug Platform

(CNBC) Nov 25, 2014 - Synthon Biopharmaceuticals today announced that the first patients with metastatic solid tumors have commenced treatment with its investigational anti-HER2 antibody-drug conjugate (ADC), SYD985.
read article 

Stem Cell Transplant Death - What Went Wrong

(BBC News) Nov 25, 2014 - Doctors at London's renowned children's hospital - Great Ormond Street - were baffled when a treatment that they routinely used to treat sick children with cancer inexplicably stopped working.
read article 

One-Two Punch of Drugs Better Than Either Alone Against Colorectal Cancer

(UCCC/In the Lab blog) Nov 25, 2014 - Genes make proteins and proteins tell your body’s cells what to do: one talks to the next, which talks to the next, and to the next. Like a game of telephone, researchers call these “signaling pathways”.
read article 

Study By UCLA Scientists Reveals New Findings About Cause of Lesions Around Jaw Bone

(UCLA) Nov 24, 2014 - Osteonecrosis of the jaw is a debilitating and painful condition in which oral lesions develop in individuals taking drugs such as bisphosphonate or denosumab, which are commonly used in treatments for osteoporosis and for cancers that have spread to the bones.
read press release 

Link Gene to Tamoxifen-Resistant Breast Cancers

(HealthNewsDigest.com) Nov 24, 2014 - After mining the genetic records of thousands of breast cancer patients, researchers from the Johns Hopkins Kimmel Cancer Center have identified a gene whose presence may explain why some breast cancers are resistant to tamoxifen, a widely used hormone treatment generally used after surgery, radiation and other chemotherapy.
read article 

New Drugs Treat Advanced Stages of a Common Skin Cancer

(Wall Street Journal) Nov 24, 2014 – The incidence of melanoma has been rising for at least 30 years, according to the American Academy of Dermatology, and several new drugs in recent years have improved survival rates in advanced cases.
read article (paid subscription required) 

Novartis Announces Extension to FDA Review Period For Multiple Myeloma Investigational Compound LBH589

(Novartis) Nov 25, 2014 - Novartis announced today that the US Food and Drug Administration (FDA) has extended their priority review period by up to three months for the new drug application (NDA) of LBH589 (panobinostat) in combination with bortezomib and dexamethasone for patients with previously treated multiple myeloma.
read corporate press release 

Roche's Genentech Defends Supply Shift For Top Cancer Drugs

(Reuters) Nov 24, 2014 - Genentech, U.S. biotech unit of Roche Holding, faces growing pressure over a decision to allow only a handful of distributors to supply three of the world's most widely used cancer drugs, a move that prominent hospitals say will create delays and raise costs.
read article 

Less Painful Mammograms? New Device May Safely Minimize the Hurt

(Today.com/NBCNews.com) Nov 25, 2014 - Melanie Kwestel’s last mammogram was so excruciating she hasn’t gone back for another in four years.
read article 

AstraZeneca Plots $200 Million Expansion in Frederick

(Baltimore Business Journal) Nov 21, 2014 - Drug giant AstraZeneca will expand its biologics manufacturing center in Frederick, Maryland, and add hundreds of jobs to its operations there.
read article 

FDA Issues Additional Guidance For Outsourcing Facilities That Compound Sterile Human Drugs

(FDA.gov) Nov 21, 2014 - Today, the U.S. Food and Drug Administration issued three additional policy documents to assist entities that compound sterile human drugs with registering as outsourcing facilities.
read press release 

Omnicare and McKesson Expand Distribution Agreement

(McKesson) Nov 24, 2014 - Omnicare Inc. and McKesson Corporation announced the signing of an expanded agreement to include the sourcing and distribution of branded, specialty and generic pharmaceuticals.
read corporate press release 

Merck Buys Rights to NewLink's Experimental Ebola Vaccine

(Reuters) Nov 24, 2014 - Merck & Co Inc will buy worldwide commercial rights to NewLink Genetics Corp's experimental Ebola vaccine.
read article 

BioMarin Expands Reach By Buying Prosensa For Up to $840 Million

(TheStreet) Nov 24, 2014 - BioMarin Pharmaceuticals is expanding its reach into the market for rare-disease therapies with a deal to buy Prosensa Holding for up to $840 million, the companies said Monday.
read article 

Costly Care at Hospital Practices

(MedPage Today) Nov 23, 2014 - Patients in physician practices owned by large hospitals and multihospital delivery systems had higher expenditures for care than patients in practices owned by the physicians themselves, a new study has found.
read article (free registration required) 

New ICR Chief's Three-Pronged Attack on Cancer

(PharmaTimes [UK]) Nov 24, 2014 - Paul Workman, the new chief executive of the Institute of Cancer Research in London has pledged to attack the disease’s ability to evolve and evade treatment.
read article